| Symbol
| ADORA2A
| contributors: mct/npt/pgu - updated : 12-02-2013
|
| HGNC name
| adenosine A2a receptor
|
| HGNC id
| 263
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
|
| loss of function
|
selective inactivation of ADORA2A in striatal neurons enhances working memory and reversal learning (  | |
| Susceptibility
|
to modification of age at onset in Huntington's disease to habitual caffeine consumption |
| Variant & Polymorphism
other
| rs5751876 T/T genotype have an earlier age at onset of 3.8 years as compared to C/C genotype |
|
probability of having the ADORA2A 1083TT genotype decreases as habitual caffeine consumption increases |
| 
|
Candidate gene
| Marker
| its expression in peripheral blood mononuclear cells may be a valuable means of differentiating amnestic mild cognitive impairment and multiple cognitive domain mild cognitive impairment | |
| Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| dermatology | skin | | |
| pharmacological A2AR blockade can be used to diminish scarring while improving the collagen composition and tensile strength of the healed wound | | neurology | neurodegenerative | huntington chorea | |
| novel therapeutic pathway of A2A receptor in HD and further strengthen the concept that the ADORA2A can be a drug target in treating HD |
| | |